Shukaib Arslan

786 total citations
30 papers, 228 citations indexed

About

Shukaib Arslan is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Oncology. According to data from OpenAlex, Shukaib Arslan has authored 30 papers receiving a total of 228 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 14 papers in Public Health, Environmental and Occupational Health and 9 papers in Oncology. Recurrent topics in Shukaib Arslan's work include Hematopoietic Stem Cell Transplantation (14 papers), Acute Lymphoblastic Leukemia research (13 papers) and Acute Myeloid Leukemia Research (8 papers). Shukaib Arslan is often cited by papers focused on Hematopoietic Stem Cell Transplantation (14 papers), Acute Lymphoblastic Leukemia research (13 papers) and Acute Myeloid Leukemia Research (8 papers). Shukaib Arslan collaborates with scholars based in United States, Italy and Germany. Shukaib Arslan's co-authors include Monzr M. Al Malki, Ryotaro Nakamura, Haris Ali, Guido Marcucci, Stephen J. Forman, Ibrahim Aldoss, Ahmed Aribi, Anthony S. Stein, Amandeep Salhotra and Sanjeet Dadwal and has published in prestigious journals such as Blood, Journal of Controlled Release and British Journal of Haematology.

In The Last Decade

Shukaib Arslan

22 papers receiving 224 citations

Peers

Shukaib Arslan

HEMAT

ONCOL

EPIDE

IMMUN

Reem Elfeky United Kingdom

Rabah Redjoul France

Xuying Pei China

Phillippe Armand United States

Margarida Silverman United States

Sharon Sen United States

Dušan Prevalšek Germany

Clara Mariette France

Anja M. Jansen-Hoogendijk Netherlands

Joanne Filicko United States

Reem Elfeky United Kingdom

Shukaib Arslan

137 ×1.0

HEMAT

30 ×0.4

42 ×0.7

ONCOL

54 ×1.1

EPIDE

98 ×2.2

IMMUN

Citations per year, relative to Shukaib Arslan Shukaib Arslan (= 1×) peers Reem Elfeky

Countries citing papers authored by Shukaib Arslan

Since Specialization

Citations

This map shows the geographic impact of Shukaib Arslan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shukaib Arslan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shukaib Arslan more than expected).

Fields of papers citing papers by Shukaib Arslan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shukaib Arslan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shukaib Arslan. The network helps show where Shukaib Arslan may publish in the future.

Co-authorship network of co-authors of Shukaib Arslan

This figure shows the co-authorship network connecting the top 25 collaborators of Shukaib Arslan. A scholar is included among the top collaborators of Shukaib Arslan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shukaib Arslan. Shukaib Arslan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Koreth, John, Jeremy Pantin, Shukaib Arslan, et al.. (2025). Primary results from Equator, a Phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease.. Blood. 146(Supplement 1). 274–274.

Nguyễn, Kim, Dat Ngo, Vaibhav Agrawal, et al.. (2025). The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B‐ ALL With High Disease Burden. American Journal of Hematology. 100(12). 2209–2219.

Rosa, Corinna La, Ibrahim Aldoss, Dongyun Yang, et al.. (2023). CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients after Stem Cell Transplant. Transplantation and Cellular Therapy. 29(2). S68–S69. 1 indexed citations

Ngo, Dat, Brian Lee, Ibrahim Aldoss, et al.. (2023). AML-408 Comparing Intensive Purine Analogues Regimens With Cladribine and Fludarabine: CLIA-Venetoclax vs FLAG-Ida-Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia During a Fludarabine Shortage. Clinical Lymphoma Myeloma & Leukemia. 23. S298–S299. 2 indexed citations

Scott, Jonathan, et al.. (2023). Autoimmune Hemolytic Anemia in a Patient With COVID-19 Pneumonia: A Case Report on a Rare Presentation. Cureus. 15(11). e49067–e49067.

Rosa, Corinna La, Ibrahim Aldoss, Dongyun Yang, et al.. (2023). Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus‐specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis. American Journal of Hematology. 98(4). 588–597. 4 indexed citations

Arslan, Shukaib, Shaun Fleming, Nitin Jain, et al.. (2022). Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial. Blood. 140(Supplement 1). 9091–9093.

Yao, Janny M., Hanna Kim, Dongyun Yang, et al.. (2022). Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis. Blood. 140(Supplement 1). 7580–7582.

Otoukesh, Salman, Hany Elmariah, Dongyun Yang, et al.. (2021). Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy. 28(2). 111.e1–111.e8. 12 indexed citations

10.

Malki, Monzr M. Al, Ni‐Chun Tsai, Joycelynne Palmer, et al.. (2021). Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. Blood Advances. 5(12). 2650–2659. 32 indexed citations

11.

Yao, Janny M., Dongyun Yang, Mary C. Clark, et al.. (2021). Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone Marrow Transplantation. 57(2). 232–242. 3 indexed citations

12.

Arslan, Shukaib, Samer K. Khaled, & Ryotaro Nakamura. (2021). Current Management and New Developments in the Treatment of Myelodysplastic Syndrome. Cancer treatment and research. 181. 115–132.

13.

Ali, Haris, Dat Ngo, Ahmed Aribi, et al.. (2021). Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. Transplantation and Cellular Therapy. 27(11). 938.e1–938.e6. 40 indexed citations

14.

Ball, Brian, Shukaib Arslan, Paul Koller, et al.. (2021). Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias. Blood. 138(Supplement 1). 3430–3430. 1 indexed citations

15.

Arslan, Shukaib, Vinod Pullarkat, & Ibrahim Aldoss. (2021). Indications for Allogeneic HCT in Adults with Acute Lymphoblastic Leukemia in First Complete Remission. Current Treatment Options in Oncology. 22(7). 63–63. 7 indexed citations

16.

Aldoss, Ibrahim, Jianying Zhang, Matthew Mei, et al.. (2020). Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia. American Journal of Hematology. 95(10). 1193–1199. 27 indexed citations

17.

Arslan, Shukaib & Ryotaro Nakamura. (2020). Decision Analysis of Transplantation for Patients with Myelodysplasia: “Who Should We Transplant Today?”. Current Hematologic Malignancy Reports. 15(4). 305–315. 1 indexed citations

18.

Wang, Juan, O. Yu. Zolotarskaya, Amrita Sule, et al.. (2020). PEAMOtecan, a novel chronotherapeutic polymeric drug for brain cancer. Journal of Controlled Release. 321. 36–48. 7 indexed citations

19.

Arslan, Shukaib, Anthony S. Stein, Stephen J. Forman, Ryotaro Nakamura, & Monzr M. Al Malki. (2020). Ibrutinib for Pure Red Cell Aplasia after Allogeneic Hematopoietic Stem Cell Transplant with Major ABO Incompatibility. Biology of Blood and Marrow Transplantation. 26(3). S362–S363.

20.

Arslan, Shukaib, Mark R. Litzow, Nathan W. Cummins, et al.. (2019). Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection. Biology of Blood and Marrow Transplantation. 25(8). e260–e267. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact